Other equities analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Mustang Bio from a hold rating to a buy rating and set a $7.25 target price on the stock in a report on Saturday, August 18th. ValuEngine raised shares of Mustang Bio from a sell rating to a hold rating in a report on Tuesday, October 9th.
MBIO stock opened at $3.88 on Tuesday. Mustang Bio has a 52 week low of $3.70 and a 52 week high of $12.89. The firm has a market cap of $109.05 million, a P/E ratio of -5.17 and a beta of 0.24.
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its holdings in shares of Mustang Bio by 904.5% during the 1st quarter. BlackRock Inc. now owns 21,646 shares of the company’s stock valued at $237,000 after purchasing an additional 19,491 shares during the last quarter. Spark Investment Management LLC bought a new position in shares of Mustang Bio during the 2nd quarter valued at $217,000. A.R.T. Advisors LLC bought a new stake in Mustang Bio in the 1st quarter worth $186,000. Northern Trust Corp grew its holdings in Mustang Bio by 76.7% in the 1st quarter. Northern Trust Corp now owns 28,364 shares of the company’s stock worth $310,000 after acquiring an additional 12,316 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new stake in Mustang Bio in the 2nd quarter worth $216,000. 9.52% of the stock is currently owned by institutional investors.
Mustang Bio Company Profile
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma.
Read More: The Discount Rate – What You Need to Know
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.